Erdafitinib, a cancer drug approved for treating advanced bladder cancer, has sparked online interest among teenagers seeking to increase their height. The drug blocks fibroblast growth factor receptors, or FGFRs, proteins that control cell growth and division.

Reports document cases where children receiving erdafitinib for brain tumours experienced unexpected growth spurts. Researchers in Vienna described two children who grew more than expected while taking the drug. One 15-year-old boy grew 14.3 centimetres over nine months, far exceeding typical growth rates for that period.

The mechanism behind this effect involves FGFR3, a receptor that normally acts as a brake on bone growth during childhood and adolescence. By blocking FGFR3, erdafitinib may release this biological restriction. However, the rapid growth documented in these cases came with serious skeletal abnormalities, including spinal deformities requiring corrective surgery.

Justin Stebbing, a professor of biomedical sciences at Anglia Ruskin University, explains that accelerating bone growth without coordinated development of muscles, ligaments and joints can result in deformities, abnormal spinal curvature and poor bone mineralisation. Erdafitinib also carries unrelated side effects, including elevated blood phosphate levels and serious eye problems that may threaten vision.

The reported cases involve very small numbers of seriously ill children receiving multiple treatments. These reports cannot demonstrate whether erdafitinib would safely increase final height in healthy adolescents or whether any extra growth would be sustained, proportionate and accompanied by normal bone strength.

TikTok has banned some accounts from promoting erdafitinib for height gain. Once puberty is complete, growth plates normally fuse and bones can no longer lengthen. No credible evidence shows erdafitinib can make fully grown adults taller.